Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6461269 | 0.89 | KMT2A (0.40) | FFAR1KMT2AF2ELANE | |
| SCHEMBL6460113 | 0.82 | CTNNB1 (0.36) | KMT2AF2ELANE | |
| SCHEMBL5250987 | 0.78 | FFAR1 (0.75) | FFAR1POLB | |
| SCHEMBL10523729 | 0.78 | MMP9 (0.63) | FFAR1POLBTDP1L3MBTL1 | |
| SCHEMBL6465725 | 0.76 | TDP1 (0.50) | FFAR1KMT2APOLBTDP1L3MBTL1 | |
| SCHEMBL17144644 | 0.73 | FFAR1 (0.44) | FFAR1KMT2A | |
| SCHEMBL10260682 | 0.73 | FFAR1 (0.62) | FFAR1KMT2APOLBTDP1L3MBTL1 | |
| SCHEMBL1586362 | 0.72 | PLA2G4B (0.50) | POLBL3MBTL1 | |
| SCHEMBL1503531 | 0.71 | PKM (0.56) | POLBL3MBTL1 | |
| SCHEMBL12855509 | 0.71 | KMT2A (0.45) | KMT2APOLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1474400-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)] -6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068756-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)]-6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | F7, HABP2, F13B | FFAR1 3663/4885KMT2A 1487/4885POLB 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.